Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 3/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8775525 | 0.93 | NR1H2 (0.48) | NR1H2USP30USP2SMN1; SMN2HPGD | |
| SCHEMBL4985158 | 0.86 | USP30 (0.44) | NR1H2USP30USP2SMN1; SMN2HPGD | |
| SCHEMBL4774218 | 0.86 | USP30 (0.43) | NR1H2USP30USP2SMN1; SMN2HPGD | |
| SCHEMBL21197351 | 0.85 | USP30 (0.43) | NR1H2USP30USP2SMN1; SMN2HPGD | |
| SCHEMBL31171502 | 0.84 | USP30 (0.40) | NR1H2USP30USP2SMN1; SMN2HPGD | |
| SCHEMBL31171500 | 0.84 | USP30 (0.47) | NR1H2USP30USP2SMN1; SMN2HPGD | |
| SCHEMBL31645803 | 0.84 | USP30 (0.42) | NR1H2USP30USP2SMN1; SMN2HPGD | |
| SCHEMBL21197226 | 0.83 | USP30 (0.44) | NR1H2USP30USP2SMN1; SMN2HPGD | |
| SCHEMBL15577659 | 0.83 | USP30 (0.40) | NR1H2USP30USP2SMN1; SMN2HPGD | |
| SCHEMBL18838278 | 0.83 | USP30 (0.43) | NR1H2USP30USP2SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3312164-B1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES LLC (US) | 2020-12-09 | — | — | EP | disclosed |
| EP-3312164-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | Calitor Sciences, LLC (US) | 2018-04-25 | — | — | EP | disclosed |
| EP-3122729-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | Calitor Sciences, LLC (US) | 2017-02-01 | — | — | EP | disclosed |
| WO-2016190847-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES, LLC (US) | 2016-12-01 | — | — | WO | disclosed |
| US-9403801-B2 | Substituted heteroaryl compounds and methods of use | CALITOR SCIENCES, LLC (US) | 2016-08-02 | — | — | US | disclosed |
| US-20150274704-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-10-01 | — | — | US | disclosed |
| WO-2015148867-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES, LLC (US) | 2015-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274704-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | PRKACA, PRKDC, PRKACB | NR1H2 976/4885USP30 1127/4885USP2 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.